1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Alexza's Adasuve crosses US finish line, but distribution limited

 
• By Donna Young

Right on schedule, Alexza Pharmaceuticals won a late-afternoon US approval on 21 December to market its inhaled antipsychotic Adasuve (loxapine) to treat agitation associated with schizophrenia or bipolar I disorder in adults, although the drug came with and a black-box warning and must be dispensed through a restricted distribution program, which likely was the trigger for the sell-off of the firm's shares.

Right on schedule, Alexza Pharmaceuticals won a late-afternoon US approval on 21 December to market its inhaled antipsychotic Adasuve (loxapine) to treat agitation associated with schizophrenia or bipolar I disorder in adults, although the drug came with and a black-box warning and must be dispensed through a restricted distribution program, which likely was the trigger for the sell-off of the firm's shares.

Mountain View, California-based Alexza's stock closed at $5.79, a loss of 6.7%, or 4 cents. But in after-hours trading, the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 
• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

More from Therapeutic Category

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?